Abstract
There are some uncontrolled studies about the efficacy and safety of both aripiprazole and risperidone for treating tic disorder. Moreover, the efficacy of these medications has never been compared. This is the first double blind randomized clinical trial comparing the safety and efficacy of aripiprazole and risperidone for treating patients with tic disorder. Sixty children and adolescents with tic disorder were randomly allocated into one of the two groups to receive either aripiprazole or risperidone for 2 months. The primary outcome measure was the score of Yale Global Tic Severity Scale. In addition, health related quality of life and adverse events were assessed. Both aripiprazole and risperidone decreased the Yale Global Tic Severity Scale score during this trial. Moreover, both medications increased the health related quality of life score. Both aripiprazole and risperidone were tolerated well. Aripiprazole [3.22 (1.9) mg/day] decreased tic score as much as risperidone [0.6 (0.2) mg/day]. Their adverse effects and their effects on health related quality of life were comparable. However, risperidone increased the patients’ social functioning more than aripiprazole in short term.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Ghanizadeh A, Mosallaei S (2009) Psychiatric disorders and behavioral problems in children and adolescents with Tourette syndrome. Brain Dev 31:15–19
Roessner V et al (2013) Pharmacological treatment of tic disorders and Tourette syndrome. Neuropharmacology 68:143–149
Zinner SH et al (2012) Peer victimization in youth with Tourette syndrome and other chronic tic disorders. Child Psychiatry Hum Dev 43:124–136
Swain JE et al (2007) Tourette syndrome and tic disorders: a decade of progress. J Am Acad Child Adolesc Psychiatry 46:947–968
Singer HS (2010) Treatment of tics and Tourette syndrome. Curr Treat Options Neurol 12:539–561
Pringsheim T et al (2012) Canadian guidelines for the evidence-based treatment of tic disorders: pharmacotherapy. Can J Psychiatry 57:133–143
Weisman H et al (2013) Systematic review: pharmacological treatment of tic disorders—efficacy of antipsychotic and alpha-2 adrenergic agonist agents. Neurosci Biobehav Rev 37:1162–1171
Scahill L et al (2003) A placebo-controlled trial of risperidone in Tourette syndrome. Neurology 60:1130–1135
Bruggeman R et al (2001) Risperidone versus pimozide in Tourette’s disorder: a comparative double-blind parallel-group study. J Clin Psychiatry 62:50–56
Dion Y et al (2002) Risperidone in the treatment of Tourette syndrome: a double-blind, placebo-controlled trial. J Clin Psychopharmacol 22:31–39
Gaffney GR et al (2002) Risperidone versus clonidine in the treatment of children and adolescents with Tourette’s syndrome. J Am Acad Child Adolesc Psychiatry 41:330–336
Eddy CM, Rickards HE, Cavanna AE (2011) Treatment strategies for tics in Tourette syndrome. Ther Adv Neurol Disord 4:25–45
Gulisano M et al (2011) Cardiovascular safety of aripiprazole and pimozide in young patients with Tourette syndrome. Neurol Sci 32:1213–1217
Ghanizadeh A (2012) Systemic review of aripiprazole for the treatment of children and adolescents with tic disorders. Neurosciences 17:200–204
Lyon GJ et al (2009) Aripiprazole in children and adolescents with Tourette’s disorder: an open-label safety and tolerability study. J Child Adolesc Psychopharmacol 19:623–633
Yoo HK et al (2011) Open-label study comparing the efficacy and tolerability of aripiprazole and haloperidol in the treatment of pediatric tic disorders. Eur Child Adolesc Psychiatry 20:127–135
Ghanizadeh A, Mohammadi MR, Yazdanshenas A (2006) Psychometric properties of the Farsi translation of the kiddie schedule for affective disorders and schizophrenia—present and lifetime version. BMC Psychiatry 6:10
Leckman JF et al (1989) The Yale Global Tic Severity Scale: initial testing of a clinician-rated scale of tic severity. J Am Acad Child Adolesc Psychiatry 28:566–573
Ghanizadeh A, Sahraeizadeh A, Berk M (2013) A head-to-head comparison of aripiprazole and risperidone for safety and treating autistic disorders, a randomized double blind clinical trial. Child Psychiatry Hum Dev. doi:10.1007/s10578-013-0390-x
Varni JW et al (2012) Effect of aripiprazole 2 to 15 mg/d on health-related quality of life in the treatment of irritability associated with autistic disorder in children: a post hoc analysis of two controlled trials. Clin Ther 34:980–992
Asadabadi M et al (2013) Celecoxib as adjunctive treatment to risperidone in children with autistic disorder: a randomized, double-blind, placebo-controlled trial. Psychopharmacology (Berl) 225:51–59
Gabbay V et al (2012) A double-blind, placebo-controlled trial of omega-3 fatty acids in Tourette’s disorder. Pediatrics 129:e1493–e1500
Storch EA et al (2011) Defining treatment response in pediatric tic disorders: a signal detection analysis of the Yale Global Tic Severity Scale. J Child Adolesc Psychopharmacol 21:621–627
Jafari P et al (2011) Health-related quality of life of Iranian children with attention deficit/hyperactivity disorder. Qual Life Res 20:31–36
Ghanizadeh A, Jafari P (2010) Cultural structures of the Persian parents’ ratings of ADHD. J Atten Disord 13:369–373
Acknowledgments
This study was the undergraduate thesis of Dr. Alireza Haghighi. This study was supported by a Grant (No. 3228) from Shiraz University of Medical Sciences. The authors would like to thank Dr. Nasrin Shokrpour at Center for Development of Clinical Research of Nemazee Hospital for editorial assistance.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ghanizadeh, A., Haghighi, A. Aripiprazole Versus Risperidone for Treating Children and Adolescents with Tic Disorder: A Randomized Double Blind Clinical Trial. Child Psychiatry Hum Dev 45, 596–603 (2014). https://doi.org/10.1007/s10578-013-0427-1
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10578-013-0427-1